Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19705886 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL19705885 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL26940074 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL19705884 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL8395652 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL19705995 | 1.00 | CYP3A4 (0.73) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL14564699 | 0.98 | CYP3A4 (0.68) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL8396968 | 0.93 | — | — | |
| SCHEMBL23591881 | 0.88 | CYP3A4 (0.57) | CYP3A4ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL1544580 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998989-B2 | 2-Imino-1,3-thiazoline-based compounds and T-type calcium channel inhibitors containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-08-16 | — | — | US | disclosed |
| US-7998989-B2 | 2-Imino-1,3-thiazoline-based compounds and T-type calcium channel inhibitors containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-08-16 | — | — | US | disclosed |
| US-20080293786-A1 | NOVEL 2-IMINO-1,3-THIAZOLINE-BASED COMPOUNDS AND T-TYPE CALCIUM CHANNEL INHIBITORS CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-11-27 | — | — | US | disclosed |
| US-20080293786-A1 | NOVEL 2-IMINO-1,3-THIAZOLINE-BASED COMPOUNDS AND T-TYPE CALCIUM CHANNEL INHIBITORS CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293786-A1 | NOVEL 2-IMINO-1,3-THIAZOLINE-BASED COMPOUNDS AND T-TYPE CALCIUM CHANNEL INHIBITORS CONTAINING THE SAME | CACNA1I, CACNA1H, CACNA1G | CYP3A4 4138/4885ALDH1A1 2247/4885TP53 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.